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Abstract
Background: Double stranded RNA (dsRNA) has multiple anti-tumor mechanisms. Over the past several decades,
there have been numerous attempts to utilize synthetic dsRNA to control tumor growth in animal models and
clinical trials. Recently, it became clear that intracellular dsRNA is more effective than extracellular dsRNA on
promoting apoptosis and orchestrating adaptive immune responses. To overcome the difficulty in delivering a
large dose of synthetic dsRNA into tumors, we propose to deliver a RNA replicase-based plasmid DNA,
hypothesizing that the dsRNA generated by the replicase-based plasmid in tumor cells will inhibit tumor growth.
Methods: The anti-tumor activity of a plasmid (pSIN-b) that encodes the sindbis RNA replicase genes (nsp1-4) was
evaluated in mice with model tumors (TC-1 lung cancer cells or B16 melanoma cells) and compared to a
traditional pCMV-b plasmid.
Results: In cell culture, transfection of tumor cells with pSIN-b generated dsRNA. In mice with model tumors,
pSIN-b more effectively delayed tumor growth than pCMV-b, and in some cases, eradicated the tumors.
Conclusion: RNA replicase-based plasmid may be exploited to generate intracellular dsRNA to control tumor
growth.
Background
Double stranded RNA has multiple anti-tumor mechan-
isms that may be potentially exploited to control tumor
growth. It is known to be pro-apoptotic, anti-proliferative,
and anti-angiogenic [1-3]. It is also a potent inducer of
type I interferons (IFN-a/b) [2,4], which are pro-apoptotic
and immuno-stimulatory as well [1,2,5]. Intracellular
dsRNA can activate various pathways, including anti-
proliferative dsRNA dependent protein kinase (PKR), IFN
inducible 2’-5’-adenylate synthetase/Rnase L system, and
oligo A synthetase [4,6,7], which can lead to apoptosis.
Intracellular dsRNA is recognized primarily by retinoic
acid-inducible gene I (RIG-1) and melanoma differentia-
tion-associated gene 5 (Mda5) [8-10]. Extracellular dsRNA
recognition occurs by Toll-like receptor (TLR3) mem-
brane bound receptor [8,11].
Over the past several decades, there had been numer-
ous attempts to utilize synthetic dsRNA such as polyri-
boinosinic-polyribocytidylic acid, poly (I:C), to control
tumors in animal models and clinical trials [3,12-14]. In
general, it was found that synthetic dsRNA only slightly
delayed tumor growth [15-17]. Increasing the dose of
the synthetic dsRNA to improve its anti-tumor activity
is not feasible because of the dose-dependent severe
adverse effects [15,18]. Recently, there is a reviving
interest in exploiting the anti-tumor activity of synthetic
dsRNA by improving the delivery of dsRNA into tumor
cells [19]. For example, Shir et al. (2006) reported the
total regression of implanted human breast cancers or
glioblastoma in mouse models when poly (I:C) was
intratumorally injected and targeted into the tumor cells
using epidermal growth factor as a ligand [19]. Using
B16-F10 melanoma in a mouse model, Fujimura et al.
(2006) reported the elicitation of tumor-specific CD8
+
T lymphocyte responses by peritumoral injection of poly
(I:C) [3]. Others have exploited the immuno-stimulatory
activity of dsRNA by immunizing with tumor cells with
intracellular synthetic dsRNA [20]. It became clear that
intracellular dsRNA was more effective than extracellu-
lar dsRNA in promoting tumor cells to undergo apopto-
sis and orchestrating the initiation of adaptive immune
responses [20-22].
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positive stranded RNA encoding its own RNA replicase
[23,24]. An anti-sense RNA is transcribed, and it func-
tions as a template for the synthesis of sense RNA.
RNA-dependent RNA polymerase activity was found on
the nonstructural protein (nsP4) [25,26]. Sindbis viral
vectors deficient in replication genes have been shown
to efficiently target and kill tumor cells in vivo [27-29].
However, concerns regarding uncontrolled vector propa-
gation and toxicity suggest that non-viral based plasmids
may offer a safer alternative [30]. Previously, the repli-
case genes (nsp1-4) from sindbis virus have been cloned
into a plasmid and placed under the control of cytome-
galovirus (CMV) promoter [23]. When transfected into
cells, the replicase genes are expressed, and the resultant
replicase complex allowed the formation of intracellular
dsRNA [23,31]. Therefore, we sought to deliver the
replicase-based plasmid into tumor cells, hypothesizing
that the RNA replicase based plasmid will generate
dsRNA inside tumor cells and inhibit the tumor growth.
This strategy is advantageous because it would avoid the
delivery of a large dose of synthetic dsRNA in vivo,
which is rather challenging; while there have been cases
of successful delivery of DNA into tumor cells [30,32,33].
Another advantage of utilizing plasmid DNA is that the
unmethylated CpG motifs on the plasmid are also
immuno-stimulatory [34,35]. CpG motifs were shown to
have anti-tumor activity by activating natural killer cells
and by inducing the secretion of cytokines such as IL-6,
TNF-a, and IFN-g [34].
In the present study, a sindbis replicase-based plasmid
pSIN-b was used. In the plasmid, the sindbis nsp1-4
g e n e sw e r eu n d e rt h ec o n t r o lo faC M Vp r o m o t e r[ 2 3 ] .
Using a model mouse lung cancer cell line, TC-1, it was
s h o w nt h a tw h e nt r a n s f e c t e di n t oc e l l si nc u l t u r e ,t h e
pSIN-b generated dsRNA, and the resultant dsRNA
seemed to be pro-apoptotic. In mouse model, the pSIN-
b significantly inhibited the growth of the TC-1 tumors.
Similar anti-tumor activity was also observed when the
pSIN-b was used to treat B16 melanoma in mice.
Methods
Plasmids
Plasmid pCMV-b was from the American Type Culture
Collection (ATCC, Manassas, VA). The pSIN-b plasmid
was constructed following a previously described
method [23]. The pSIN-b-Δnsp was constructed in two
steps. First, the pSIN-b was digested with Pst I (Invitro-
gen, Carlsbad, CA), and the resultant fragment was gel
extracted and purified using a PureLink Gel Extraction
kit (Invitrogen). The DNA fragment was further digested
with Hind III (Invitrogen). The correct fragment was gel
extracted, and the adhesive ends were ligated using T4
DNA ligase (Invitrogen). All plasmids were amplified in
E. coli DH5a under selective growth conditions.
Plasmid DNA was methylated at CpG sites with CpG
methyl transferase (M.SssI) (New England BioLabs,
Beverly, MA). The M.SssI methylates at the carbon posi-
tion 5 of cytosine residues within double stranded recogni-
tion sequence. Methylation reaction containing 2 U of
methylase per μg of DNA was incubated at 37°C for at
least 3 h. The extent of methylation by the M.SssI was
determined using a BstU I endonuclease assay (Invitro-
gen). Plasmid was purified from bacteria using a QIAGEN
midiprep kit (Valencia, CA). Large scale plasmid prepara-
tion was performed by GenScript (Piscataway, NJ).
Cell lines and culture
Mouse lung tumor cells (TC-1, ATCC, CRL-2785) and
mouse melanoma cells (B16-F10, ATCC, CRL-6475)
were cultured in RPMI 1640 medium (Invitrogen) and
DMEM medium (Invitrogen), respectively. The media
were supplemented with 10% fetal bovine serum (FBS,
Invitrogen), 100 U/ml of penicillin (Invitrogen), and
100 μg/ml of streptomycin (Invitrogen).
The ovalbumin (OVA)-expressing B16-OVA cell line
was generously provided by Dr. Edith M. Lord and
Dr. John Frelinger (University of Rochester Medical
Center, Rochester, NY) [36]. B16-OVA cells were cul-
tured in RPMI 1640 medium supplemented with 5%
FBS and 400 μg/ml of G418 (Sigma).
In vitro Transfection
TC-1 cells were seeded in 24 or 48 well plates (20 000
cells/well) and incubated at 37°C, 5% CO2 for 24 h or
until 60% confluency followed by transfection using
plasmid DNA (0.15 or 0.40 μg as where mentioned)
complexed with Lipofectamine
® (Invitrogen) following
the manufacturer’s instruction. The transfection medium
was replaced with fresh medium 3 h later.
Semi quantitative RT-PCR
Total RNA was isolated from TC-1 cells (1 × 10
7) trans-
fected with plasmid using a QIAGEN RNeasy mini kit.
On-column DNase digestion was performed using
RNase-free DNase set (QIAGEN) to eliminate DNA
contamination. The RNA quality was assessed using the
OD260/OD280 ratio.
Reverse transcriptase reaction was performed using Invi-
trogen SuperScript III™kits (Cat No. 11752-050 or No.
18080-093) with oligo dT primers or sindbis nsp4 gene
specific primers (nsp4-1, p4F (5’-CCGGAATGTTCCT-
CACACTT-3’)a n dp 4 R( 5 ’-GGAATGCTTTTGCTCT
GG-3’)). Polymerase chain reaction was completed utiliz-
ing cDNA from the reverse transcription and primer set
p4F/p4R, which amplified a 501 base pair fragment of the
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Mastercycler (Hauppauge, NY) for 30 cycles: 94°C for
5 min, 94°C for 30 s, 55°C for 30 s, 72°C for 30 s, and a
5 min final extension at 72°C. The nsp4 gene fragment
was amplified using platinum taq DNA polymerase (Invi-
trogen). The PCR products (25 μl) were analyzed using
agarose gel electrophoresis.
Enzyme-linked immunosorbent assay (ELISA)
T h ep r e s e n c eo fd s R N Ai nT C - 1c e l l s( n=3 )t r a n s -
fected with the plasmid was confirmed using ELISA as
previously described with modification [37]. Briefly,
96-well plates were coated at 4°C overnight with 1 μg
total RNA diluted in PBS. Plates were washed with PBS/
Tween 20 (10 mM, pH 7.4, 0.05% Tween 20, Sigma-
Aldrich, St. Louis, MO) and blocked with 4% (w/v)
bovine serum albumin (BSA, Sigma-Aldrich) in PBS/
Tween 20 for 1 h at 37°C. Plates were washed again
with PBS/Tween 20. Monoclonal anti-dsRNA antibody
J2 (English & Scientific Consulting Bt. Szirák, Hungary)
was added to each well following the removal of the
blocking solution. The plates were incubated for an
additional 3 h at 37°C. Horseradish peroxidase (HRP)
labeled goat anti-mouse IgG2a (5 000-fold dilution
Southern Biotechnology Associates, Birmingham, AL)
was added to the wells, followed by 1 h of incubation at
37°C. The presence of bound secondary antibody was
detected after a 30 min incubation with 3,3’,5,5’-tetra-
methylbenzidine substrate (TMB) (Sigma-Aldrich). The
reaction was stopped by the addition of sulfuric acid
(0.2 M, Sigma).
Determination of cell viability
The number of viable TC-1 cells was determined using
a 3-(4,5-dimethylthiazol)-2-,5-diphenyltetrazolium bro-
mide (MTT) kit (Sigma-Aldrich) 24, 48, and 72 h after
the initiation of the transfection (n = 4) [12]. Cells trea-
ted with sterile PBS were used as a control. Formula
used to calculate the relative cell number (%) was: Rela-
tive cell number = 100 × number of live cells trans-
fected with pCMV-b (pSIN-b,o rp S I N - b-Δnsp)/number
of live cells treated with sterile PBS.
Preparation of plasmid DNA-liposome lipoplexes
Cationic liposomes were prepared using cholesterol
(Sigma-Aldrich), egg phosphatidylcholine (Avanti Polar
Lipids, Inc, Alabaster, AL), and 1,2,-dioleoyl-3-trimethyla-
monium-propane (DOTAP, Avanti) at a molar ratio of
4.6:10.8:12.9 by thin film hydration method followed by
membrane extrusion (1, 0.4, and 0.1 μm, sequentially)
[38]. The final concentration of DOTAP in the liposome
was 10 mg/ml. The plasmid-liposome lipoplexes were pre-
pared by mixing equal volumes of plasmid DNA (25 μgi n
25 μl) solution and liposome suspension containing 50 μg
of DOTAP liposomes. The mixture was allowed to stay at
room temperature for at least 15 min before further use.
Particle size was measured using a Malvern Zetasizer
Nano ZS (Worcestershire, United Kingdom). The size of
the liposomes was 110 ± 0.6 nm with a polydispersity
index (PI) of 0.121. The pSIN-b-liposome lipoplexes were
255 ± 31 nm (PI, 0.177). The pCMV-b-liposome lipo-
plexes were 249 ± 33 nm (PI, 0.183). The sizes of the two
lipoplexes were not statistically different (p = 0.83, t-test,
n=3 ) .
Animal studies
All animal studies were carried out following the National
Institutes of Health animal use and care guidelines. Ani-
mal protocol was approved by the Institutional Animal
Care and Use Committee at the University of Texas at
Austin. Female C57BL/6 mice (6-8 weeks) were from
Simonsen Laboratories (Gilroy, CA) or Charles River
laboratories, Inc. (Wilmington, MA). Female athymic nude
mice (6-8 weeks) were from Charles River laboratories.
Mice were subcutaneously injected with TC-1, B16/F10,
or B16-OVA cells (5 × 10
5)i nt h er i g h tf l a n k .W h e n
tumors reached an average diameter of 3-4 mm, the plas-
mid DNA-liposome lipoplexes were injected subcuta-
neously peritumorally (s.c., p.t.) for 5 or 10 consecutive
days [12,15,19]. The dose of the plasmid DNA was 25 μg
DNA per mouse per injection. Tumor size was measured
using a digital caliper and calculated using the following
equation [39]: tumor diameter = (Length + Width)/2. To
examine whether the nsp genes were expressed in vivo,
pCMV-b,p S I N - b,o rp S I N - b-Δnsp (25 μg) was injected
into the gastrocnemius muscles in the hind legs of mice
(n = 2). After 24 h, the injected muscle tissues were col-
lected and homogenized using TRIzol reagent (Invitrogen)
to isolate total RNA. RT-PCR was performed to amplify
nsp4 gene or b-gal gene using the nsp4-1 primers or the
b-gal primers (5’-GACGTCTCGTTGCTGCATAA-3’;
5’-CAGCAGCAGACCATTTTCAA-3’).
Histology
TC-1 tumors in mice that were treated for 6 consecutive
days with plasmids were collected, fixed in formalde-
hyde, embedded in paraffin, and sectioned. Immunohis-
tochemistry was performed to detect apoptosis using the
anti-ACTIVE caspase-3 antibody (Promega, Madison,
WI) according to manufacturer protocol. Fifteen ran-
dom fields per sample at 40 × magnification were scored
for cleaved caspase-3. Apoptotic index was determined
based on the % of cleaved caspase-3 positive cells found
within total cells counted [12].
Quantification of IFN-a in mouse serum samples
Mice were subcutaneously injected with 125 μgo fp l a s -
mid DNA in lipoplexes (DNA/liposomes, 1:2, w/w). Ten
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of IFN-a was determined using a mouse IFN-a (Mu-
IFN-a) ELISA kit (PBL Biomedical Laboratories, Piscat-
away, NJ).
Statistical analysis
Statistical analyses were completed using ANOVA fol-
lowed by Fisher’s protected least significant difference
procedure. A p-value of < 0.05 (2-tail) was considered
statistically significant.
Results and discussion
Generation of dsRNA by transfecting pSIN-b into
tumor cells
Shown in Figure 1 are maps of the plasmids used. In the
pCMV-b, the b-galactosidase gene is driven by the CMV
promoter. In the pSIN-b, the nsp1-4 genes are driven by
a CMV promoter, while the b-galactosidase gene is dri-
ven by a sindbis viral subgenomic promoter. The pSIN-
b-Δnsp was constructed by deleting the nsp1-3 and part
of the nsp4 genes from the pSIN-b. To confirm that the
pSIN-b plasmid can produce dsRNA when delivered
into cells, TC-1 cells were transfected with pSIN-b,a n d
the total RNA was extracted from the cells 24 h later.
The total RNA was reverse transcribed with either oligo
dT primers or nsp4 gene specific primers (p4-F or
p4-R). The cDNA was then amplified with nsp4-specific
primers. A 501 bp nsp4 gene fragment was observed in
all samples transfected with pSIN-b, but not in cells
transfected with the pCMV-b (Figure 2A), indicating the
presence of both sense and anti-sense RNA of the nsp4
gene in cells transfected with the pSIN-b. The produc-
tion of dsRNA in cells transfected with the pSIN-b was
further confirmed using ELISA. As shown in Figure 2B,
TC-1 cells transfected with pSIN-b had an elevated level
of dsRNA compared to untransfected cells, whereas
cells transfected with pCMV-b and the untransfected
cells had a similar level of dsRNA. The dsRNA gener-
ated within cells transfected with the pSIN-b seemed to
be functional because the number of live cells in sam-
ples transfected with pSIN-b decreased gradually with
the increase in incubation time, in contrast to the
increase in the number of live cells in samples trans-
fected with the pCMV-b (Figure 2C). As expected, the
pSIN-b-Δnsp no longer caused a decrease in the num-
ber of live cells when transfected into the TC-1 tumor
cells (Figure 2C), indicating the significance of the nsp1-
4 genes for the pSIN-b plasmid to be functional. This
observation is in agreement with the finding by Leitner
et al. (2004), who showed that the survival of BHK-21
cells transfected with a replicase-based plasmid was sig-
nificantly lower than cells transfected with a conven-
tional CMV promoter-driven plasmid [40]. The cell
death after transfection with the pSIN-b was likely
caused by the pro-apoptotic dsRNA produced by the
sindbis RNA replicase complex [40]
Treatment of tumor-bearing mice with pSIN-b plasmid
caused tumor regression
Prior to carrying out tumor treatment studies, the ability
of the pSIN-b to express the nsp1-4 genes in vivo was
examined. As shown in Figure 3 using RT-PCR, nsp4
RNA expression was detected only in mouse muscle tis-
sues injected with the pSIN-b, not in the ones injected
with the pCMV-b or the pSIN-b-Δnsp, demonstrating
that only the pSIN-b was capable of expressing the nsp
genes in vivo.T h eb-gal mRNA was present in all the
mouse muscle tissues since the b-gal gene is endogen-
ous (Figure 3).
To evaluate the extent to which the pSIN-b can control
the growth of tumors pre-established in mice, mouse
TC-1 lung cancer cells were seeded in mice. When
tumors reached 3-4 mm in diameter, mice were treated
with pSIN-b or pCMV-b daily for 10 days. Mice in the
negative control group were not treated. As shown in
Figure 4A, TC-1 tumors grew significantly slower in mice
that received the pSIN-b p l a s m i dt h a ni nm i c et h a t
received the pCMV-b plasmid. In fact, 25 days after cell
seeding, only 20% or 40% of tumor-bearing mice that
were left untreated or received the pCMV-b plasmid,
respectively, were alive, but all mice that received the
pSIN-b were still alive (Table 1). Moreover, on day 25,
there was only one mouse in the group that received the
pSIN-b plasmid had a tumor of 3.1 mm in diameter,
which completely regressed on day 37 (Table 1). Clearly,
the pSIN-b plasmid was more effective in controlling the
growth of the TC-1 tumors than the pCMV-b plasmid.
Finally, mice in the negative control group were left
Figure 1 A schematic of plasmids used in this study. CMV, cytomegalovirus promoter; Lac-Z, b-galactosidase; nsp, sindbis virus sequences
coding for the nonstructural proteins (nsp1-4). pSIN-b-Δnsp (8,727 bp), pSIN-b (14,869 bp), pCMV-b (7,164 bp).
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injection of sterile PBS or the liposomes did not have any
effect on the growth of the TC-1 tumors as compared to
mice left untreated (Figure 4B), demonstrating that
potential inflammations caused by the liposomes alone or
by the peritumoral injections per se were not responsible
for the anti-tumor activity observed in Figure 4A.
The anti-tumor activity from pSIN-b required functional
replicase genes nsp1-4
To understand whether the sindbis replicase genes,
nsp1-4, were related to the anti-tumor activity of the
pSIN-b plasmid, the anti-tumor activity of the pSIN-b-
Δn s pw a sc o m p a r e dt ot h a to ft h ep S I N - b.W h e nu s e d
to treat the TC-1 tumors in mice, the pSIN-b-Δnsp
was significantly less effective in controlling the growth
of the tumors than the pSIN-b in the beginning
(Figure 5), demonstrating that the nsp1-4 genes, which
were responsible for the dsRNA production, played a
significant role in the anti-tumor activity of the pSIN-b
plasmid. It needs to be noted that the TC-1 tumor
cells are strongly immunogenic, and it was expected
the peritumoral injection of pSIN-b-Δnsp to show
anti-tumor activity because the plasmid, with CpG
motifs, can activate innate anti-tumor immune
responses [41].
Figure 2 Generation of dsRNA in tumor cells transfected with pSIN-b. (A). RT-PCR confirmed the presence of sindbis virus nsp4 gene mRNA
and its anti-sense strand in tumor cells transfected with pSIN-b. TC-1 cells were transfected with pCMV-b (pCMV) or pSin-b (pSIN), or left
untreated (N/A). Total RNA was reverse transcribed into DNA with oligo dT primer or primers specific to the nsp4 gene (forward p4F or reverse
p4R) before PCR amplification. This experiment was repeated twice with similar results. (B). ELISA confirmed the presence of an elevated level of
dsRNA in TC-1 cells transfected with pSIN-b (n = 3). Total dsRNA was isolated from TC-1 cells transfected with pCMV-b or pSIN-b and used to
coat ELISA plate. The primary Ab was the J2 anti-dsRNA IgG2a. *, p = 0.004. (C). Transfection of pSIN-b into TC-1 cells inhibited cell growth. TC-1
cells (20 000 cells/well) were transfected with the same amount (0.4 μg) of pCMV-b, pSIN-b, or pSIN-b-Δnsp (n = 4). Cell numbers were
quantified using MTT assay and normalized to cells treated with sterile PBS. Data shown are mean ± S.E.M. **, at 48 and 72 h, the value of the
pSIN-b were different from that of the pCMV-b and the pSIN-b-Δnsp (p < 0.05).
Figure 3 In vivo expression of nsp4 gene. Twenty-four h after i.
m. injection with PBS, pCMV-b, pSIN-b, or pSIN-b-Δnsp, total RNA
was extracted from the muscle tissues and RT-PCR-amplified to
detect the expression of nsp4 and b-gal genes.
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with the pSIN-b plasmid underwent apoptosis than in
tumors treated with the pCMV-b plasmid. We suspect
that the increased apoptosis in tumors that received the
pSIN-b plasmid was related to the plasmid’s ability to
produce dsRNA in transfected cells. However, it is
unclear to what extent the apoptosis was caused directly
by dsRNA produced by the pSIN-b plasmid. Double
stranded RNA is pro-apoptotic [2], but the type I IFNs
induced by dsRNA are pro-apoptotic as well [2]. More-
over, the unmethylated CpG motifs on the plasmid, the
dsRNA per se, and type I IFN are all known to be able
to activate innate immunity such as natural killer (NK)
cells, which can cause tumor death [42]. In fact, it was
shown that subcutaneous injection of the pSIN-b plas-
mid induced an elevated level of IFN-a in mouse serum
samples (Figure 7).
Adaptive immunity contributed to the anti-tumor activity
from pSIN-b
TC-1 tumor cells are highly immunogenic in C57BL/6
mice due to the human papillomavirus E6 an E7 genes in
the TC-1 cells [43]. Data from several recent studies have
shown that tumor cells with intracellular dsRNA were
more immunogenic than tumor cells physically mixed
with dsRNA [19-22]. Therefore, it was expected that
Figure 4 Treatment of mice with the pSIN-b caused TC-1 tumor regression. (A). C57BL/6 mice (n = 5) were s.c. implanted with TC-1 tumor
cells (5 × 10
5) on day 0. DNA-liposome lipoplexes were injected (s.c., p.t.) for 10 consecutive days, starting on day 5 (25 μg DNA per day). (*)
indicates that on days 13-15 the values of pCMV-b and pSIN-b were different from each other (p < 0.05). (B). Peritumoral injection of liposomes
alone or sterile PBS did not affect the growth of the TC-1 tumors. Mice (n = 5) with TC-1 tumors were injected (p.t.) with sterile PBS or liposomes in
PBS (dose equivalent to that injected in the DNA-liposome lipoplexes) for 10 consecutive days, starting on day 4. Data shown were mean ± S.E.M.
Table 1 Treatment with pSIN-b plasmid caused TC-1
tumor regression
Untreated pCMV-b pSIN-b
No. of mice alive
a 1/5 2/5 5/5
Tumor size (mm) 9.1 8.9, 6.1 0, 0, 0, 0, 3.1
b
Data shown are 25 days after tumor cell seeding into mice.
a. Shown are number of live mice/total number of mice.
b. On day 37, all mice that were treated with the pSIN-b became tumor-free.
Figure 5 Deletion of the replicase genes (nsp1-3 and part of
nsp4) from the pSIN-b plasmid significantly decreased the anti-
tumor activity of the plasmid. C57BL/6 mice (n = 4-5) were s.c.
implanted with TC-1 tumor cells (5 × 10
5) on day 0. From days 4 to
13, mice were injected (s.c., p.t.) with lipoplexes prepared with pSIN-b
(25 μg) or pSIN-b-Δnsp (25 μg). *, On day 8, p = 0.05, pSIN-b vs. pSIN-
b-Δnsp.
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extent, to the anti-tumor activity from the pSIN-b plas-
mid. To test this hypothesis, the same TC-1 tumors
established in athymic mice were treated with pSIN-b or
pCMV-b. As shown in Figure 8 the pSIN-b was no
longer more effective than the pCMV-b in controlling
the growth of the TC-1 cells, indicating that adaptive
immunity contributed to the anti-tumor activity from the
pSIN-b plasmid. However, the adaptive immunity was
not absolutely required for the pSIN-b to have anti-
tumor activity because recent preliminary data in our lab
showed that in athymic mice, the pSIN-b caused total
regression of pre-established model human tumors when
targeted into the tumor cells using a tumor-specific
ligand (Rodriguez and Cui, unpublished data).
Unmethylated CpG motifs contributed to the anti-tumor
activity of the pCMV-b
The anti-tumor effect from the pCMV-b plasmid was
likely due to the unmethylated CpG motifs present on
the plasmid [41]. As shown in Figure 9 methylation of
the pCMV-b depleted the plasmid’s ability to inhibit the
growth of the TC-1 tumor cells in mice. This is in
Figure 6 Injection with pSIN-b promoted more tumor cells to undergo apoptosis. (A). Micrographs of tumors stained against anti-caspase-
3 (brown). (B). Apoptotic index. Data shown were mean ± S.E.M. The number of mice in each group was 3-4. (*) Indicates that the value of
pSIN-b differed from that of the others (ANOVA, p = 0.03).
Figure 7 The pSIN-b plasmid induced IFN-a production in
mouse sera. IFN-a levels in blood were measured 10 h after
injection (n = 4). Data reported are means ± SEM. (*, p < 0.05,
pCMV-b vs. pSIN-b).
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DNA itself had anti-tumor activity because the
unmethylated CpG motifs on the plasmid can activate
innate immunity [41]. Therefore, it is possible that both
dsRNA produced by the RNA replicase complex
encoded by the nsp1-4 genes and the unmethylated
CpG motifs on the pSIN-b plasmid may have contribu-
ted to the anti-tumor activity from the pSIN-b.
The pSIN-b plasmid was effective against B16 melanoma
in mice as well
To test whether the pSIN-b was effective against tumors
other than the TC-1, mice with pre-established B16-F10
or B16-OVA tumors were treated similarly. As shown in
Figure 10 the pSIN-b plasmid significantly controlled
the growth of both poorly immunogenic B16-F10
tumors (Figure 10A) and the more immunogenic B16-
OVA tumors (Figure 10B), indicating that the approach
of controlling tumor growth with the replicase-based
plasmid was not limited to the TC-1 tumors and likely
not limited to highly immunogenic tumors as well.
Again, it is not surprising that the pCMV-b also showed
anti-tumor activity against the B16 melanoma. In a pre-
vious study, McCray et al. (2006) showed that intratu-
moral injection of an empty pcDNA3.1 delayed the
growth of B16 tumors, as compared to the injection of
saline [44]. It was also shown that intratumoral injection
of the pcDNA3.1 followed by in vivo electroporation
further improved the anti-tumor activity [44]. In the
present study, the repeated peritumoral injection of the
pCMV-b complexed with cationic liposomes may have
improved the non-specific anti-tumor activity from the
plasmid.
Conclusions
A RNA replicase-based plasmid that did not encode any
relevant functional gene was showed to have anti-tumor
activity. The anti-tumor activity of the RNA replicase-
encoding plasmid was likely due to its ability to allow
the transfected tumor cells to produce dsRNA and to
activate innate and adaptive immunity. In the present
study, for proof-of-concept purpose, the RNA replicase
encoding plasmid was dosed to mice by subcutaneous
peritumoral injection. Although feasible for tumors such
as head and neck cancers, certain non-metastasized mel-
anomas, and brain tumors, peritumoral or intratumoral
injection is expected to be difficult to operate for many
other solid tumors. We are in the process of developing
a liposome-based system to target the RNA replicase
encoding plasmid into tumor cells by the intravenous
route. Treatment of poorly immunogenic tumors such
as B16-F10 melanoma in animal models is a good simu-
lation of conditions observed in cancer patients [45],
and the data in the present study showed that both
Figure 8 The pSIN-b plasmid was no longer more effective
than pCMV-b against tumors in athymic mice. Mice (n = 6-8)
were s.c. implanted with TC-1 tumor cells (5 × 10
5) on day 0. From
days 4 to 13, mice were injected (s.c., p.t) with lipoplexes prepared
with pSIN-b (25 μg) or pCMV-b (25 μg).
Figure 9 Unmethylated CpG motifs contributed to the anti-
tumor activity of the pCMV-b. C57BL/6 mice (n = 5-6) were
implanted with TC-1 tumor cells (5 × 10
5) on day 0. From days 6 to
15, mice were injected (s.c., p.t.) with lipoplexes prepared with
unmethylated or methylated pCMV-b (pCMV-b or met-CMV-b,2 5
μg). Data shown were mean ± S.E.M. (*) indicates that on days 11
to 15, the values of pCMV-b and met-CMV-b were different from
each other (p < 0.05).
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Page 8 of 10highly immunogenic and poorly immunogenic solid
tumors were receptive to treatment with a RNA repli-
case based plasmid. Our results suggested a novel
approach to cancer molecular therapy.
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